Compositions and Methods for Reducing Body Fat

• US 20100234466A1
• Filed: 01/06/2010
• Published: 09/16/2010
• Est. Priority Date: 03/23/2006
• Status: Active Grant

• Current Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Original Assignee: Topokine Therapeutics, Inc. (Abbvie Incorporated)
• Inventors: Grosskreutz, Cynthia L., Pasquale, Louis R.
• Granted Patent: US 8,829,050 B2
• Time in Patent Office: Days
• US Class Current: 514/573
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 8/37 Esters of carboxylic acids
• CPC Class Codes: A61K 8/42 Amides
• CPC Class Codes: A61K 8/69 containing fluorine
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61Q 19/06 for countering cellulitis

Abstract

The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.

Claims

1. A method for reducing fat in a body of an individual, the method comprising administering to the skin of a body, in an amount sufficient to reduce fat in the body, a compound of formula I

2. The method of claim 1 wherein the compound is represented by formula II

27. The method of claim 1, wherein fat reduction occurs at a localized area.

28. The method of claim 27, wherein the localized area is selected from the group consisting of abdomen, chest, buttocks, hips, thighs, legs, knees, arms, chin, neck, face, and combinations thereof.

29. The method of claim 1, wherein the individual has excess body fat as a side effect of medication.

31. The method of claim 1, wherein the individual suffers from a condition selected from the group consisting of excess body weight, obesity, fat maldistribution syndrome, HIV, a genetic disorder characterized at least in part by excess body fat, Grave'"'"'s disease, diabetes mellitus, present or recent smoking cessation, and combinations thereof.

32. The method of claim 1, further comprising performing a cosmetic or surgical procedure.

33. The method of claim 32, wherein the procedure is selected from the group consisting of mammoplasty, blepharoplasty, abdominoplasty, lipoplasty, liposuction, rhinoplasty, botulinum toxin administration, orbital decompression, midface lift, sub-orbicularis oculi fat lift, brow lift, and combinations thereof.

34. The method of claim 1, wherein said compound is delivered in a form selected from the group consisting of an ointment, a lotion, a cream, a patch, and a transdermal system.

36. The method of claim 1, wherein the compound is in a sustained-release formulation.

38. The method according to claim 1, wherein the individual is a human.

39. The method of claim 1, wherein fat reduction comprises reducing fat as measured by at least one of volume, size, mass, bulk, density, amount, or quantity.

40. The method of claim 39, wherein the reduction of local or total fat is greater than or equal to 50 percent, greater than or equal to 25 percent, greater than or equal to 10 percent, or greater than or equal to 5 percent.

41. The method of claim 1, wherein fat reduction comprises reducing fat cell amount.

42. The method of claim 1, wherein fat reduction comprises reducing fat cell volume.

43. The method of claim 1, wherein fat reduction comprises reducing fat cell maturation.

44. The method of claim 1, wherein fat reduction comprises dedifferentiating a fat cell.

3-8. -8. (canceled)

9. A method for reducing fat in a body of an individual, the method comprising injecting into a fat deposit of a body, in an amount sufficient to reduce fat in the body, a compound of formula I

35. The method of claim 9, wherein the injection comprises at least one of a subcutaneous injection, an intramuscular injection, a retrobulbar injection, a peribulbar injection, or an intralesional injection.

10-16. -16. (canceled)

17. A method for reducing fat in a body of an individual, the method comprising implanting into a body, in an amount sufficient to reduce fat in the body, an implantable depot comprising a compound of formula I

18-26. -26. (canceled)

30. (canceled)

37. (canceled)